

# DAPAHENZ-5,10

Dapagliflozin 5 mg and 10 mg Tablets

# DAPAHENZ-M-5/1000

Dapagliflozin 5 mg and Metformin (ER) 1000 mg Tablets

# DAPAHENZ-M-10/500

Dapagliflozin 10 mg and Metformin (ER) 500 mg Tablets

# DAPAHENZ-M-10/1000

Dapagliflozin 10 mg and Metformin (ER) 1000 mg Tablets



ER - Extended Release



## DAPA-HF TRIAL

### Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

A RANDOMIZED, PLACEBO-CONTROLLED TRIAL | DURATION - 18.2 MONTHS

#### INCLUSION CRITERIA

Patients with symptomatic Heart Failure (HF), ejection fraction of 40% or less, NT-proBNP of at least 600 pg/ml (or  $\geq 400$  pg/ml if hospitalized for HF within last 12 months), atrial fibrillation or atrial flutter  $\geq 900$  pg/ml.



#### EFFICACY OUTCOMES

386 (16.3 %)	Cardiovascular death, Hospitalization for HF or urgent visit for HF (N, %)	502 (21.2 %)
237 (10 %)	Worsening heart failure (N, %)	326 (13.7 %)
227 (9.6 %)	Cardiovascular death (N, %)	273 (11.5 %)
28 (1.2 %)	Worsening renal function (N, %)	39 (1.6 %)

#### CONCLUSION

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin.



# DAPAHENZ-5,10

Dapagliflozin 5 mg and 10 mg Tablets

# DAPAHENZ-M-10/500

Dapagliflozin 10 mg and Metformin (ER) 500 mg Tablets

# DAPAHENZ-M-5/1000

Dapagliflozin 5 mg and Metformin (ER) 1000 mg Tablets

# DAPAHENZ-M-10/1000

Dapagliflozin 10 mg and Metformin (ER) 1000 mg Tablets

## Mechanism of Action :

**Dapagliflozin** is an inhibitor of Sodium-glucose transport protein 2 (SGLT2). By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin reduces renal glucose reabsorption, leading to urinary glucose excretion and a reduction in blood glucose levels.

**Metformin** decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

**Dapagliflozin** with **Metformin** provides additional reduction in blood glucose concentrations with the added benefit of modest weight loss and reduction in systolic blood pressure.

	INDICATION	DOSING
DAPAHENZ	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus	5 mg once daily, taken in the morning. The dose can be increased to 10 mg once daily
	In patients with heart failure with reduced ejection fraction, to reduce the risk of CV death and hospitalization for heart failure	10 mg once daily
	In patients with T2D with multiple CV risk factors, to reduce the risk of hospitalization for heart failure	
DAPAHENZ-M	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate	Dapahenz-M should be taken once daily in the morning with food or as prescribed by the Doctor.

## USPs :

- Convenient Once Daily Dosing
- Low Risk of Hypoglycemia
- Reduces hospitalization for heart failure
- Reduces cardiovascular death and all-cause mortality
- Prevents and reduces progression of kidney disease

References : 1. Circulation. 2019;139:2528–2536 | 2. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. | 3. Drugs. 2012 Dec 3;72(17):2289-312. | 4. Diabetes Metab Syndr Obes. 2016; 9: 25–35.

## La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India.  
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

©2022 All rights reserved, La Renon Healthcare Private Limited

I am: \_\_\_\_\_  
Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_